Aspira Women's Health Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicolette Possemato
- Full Time Employees
- 66
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Building III Austin TX United States of America 78738
- IPO Date
- Oct 2, 2000
- CIK
- 0000926617
- Website
- aspirawh.com
- Similar Companies
- Business
- Aspira Women's Health Inc. (OTCQB: AWHL) develops and commercializes AI-powered noninvasive diagnostic tests for gynecologic diseases, focusing primarily on ovarian cancer risk assessment in women with adnexal masses; its OvaSuite portfolio includes OvaWatch, a laboratory-developed test with over 99% negative predictive value for initial clinical assessment of indeterminate or benign adnexal masses offering longitudinal monitoring; Ova1Plus, a reflex process combining FDA-cleared Ova1 (greater than 96% sensitivity with clinical assessment) and Overa to detect malignancy risk in adnexal masses planned for surgery; and EndoCheck, a noninvasive diagnostic test for endometriosis in development. Founded in 1993 and headquartered in Trumbull, Connecticut, with prior operations in Austin, Texas, the company targets healthcare providers in the United States, empowering optimal patient management through biomarker analysis, menopausal status evaluation, and ultrasound integration regardless of patient ethnicity or menopausal status. Recent developments include a June 2025 partnership with Dorsata to launch an adnexal mass clinical decision-support module, expanding access to over 300 women's health practices and 1.5 million patients; a October 2025 laboratory services contract with University of Texas Medical Branch at Galveston to broaden Ova1Plus and OvaWatch distribution in Texas; a $2.95 million PIPE financing in September 2025; addition of Jane Pine Wood to the board in July 2025; transition to OTCQB trading in May 2025; and progress on ARPA-H Sprint for Women's Health program milestones.
Aspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's Health
AWH Reports First Quarter 2026 Financial Results
AWH to Hold First Quarter 2026 Earnings Conference Call on Wednesday, May 13, 2026
Aspira Women's Health (OTCQB:AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)
AWH Announces Fourth Quarter and Full Year 2025 Results
AWH Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Results and Conference Call Date
Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update
AWH Announces Third Quarter 2025 Financial Results
Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
AWH to Hold Third Quarter 2025 Earnings Conference Call on Monday, November 10, 2025
AWH Closes $9.3 Million Mortgage Financing on Three Ohio Properties
Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
Aspira Women's Health Appoints New Chief Financial Officer
Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update
AWH Announces Second Quarter 2025 Financial Results
Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors
AWH to Hold Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025
Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients
Aspira Announces First Quarter 2025 Financial Results and Provides Business Update
AWH ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS